Exicure (XCUR)
(Delayed Data from NSDQ)
$4.23 USD
+0.30 (7.63%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $4.14 -0.09 (-2.13%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Exicure, Inc. [XCUR]
Reports for Purchase
Showing records 1 - 19 ( 19 total )
Company: Exicure, Inc.
Industry: Medical - Biomedical and Genetics
Company: Exicure, Inc.
Industry: Medical - Biomedical and Genetics
Company: Exicure, Inc.
Industry: Medical - Biomedical and Genetics
Multiple Programs Advancing; 2Q21 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Exicure, Inc.
Industry: Medical - Biomedical and Genetics
High-Profile Agreement Inked With Mid-Sized Pharma Partner; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Exicure, Inc.
Industry: Medical - Biomedical and Genetics
Cavrotolimod Interim Data Imminent; 1Q21 Financial Results; Reducing PT to $6
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Exicure, Inc.
Industry: Medical - Biomedical and Genetics
Clinical and Collaboration Catalysts; 2020 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Exicure, Inc.
Industry: Medical - Biomedical and Genetics
Cavrotolimod Orphan Drug Designation Received; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Exicure, Inc.
Industry: Medical - Biomedical and Genetics
Cavrotolimod Receives Fast Track Designations; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Exicure, Inc.
Industry: Medical - Biomedical and Genetics
Company: Exicure, Inc.
Industry: Medical - Biomedical and Genetics
Friedreich''s Ataxia Program to Advance; Solid Balance Sheet; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Exicure, Inc.
Industry: Medical - Biomedical and Genetics
Cavrotolimod Advancing; 2Q20 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Exicure, Inc.
Industry: Medical - Biomedical and Genetics
Cavrotolimod Merkel Cell Carcinoma Trial Patient Dosing Initiated; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Exicure, Inc.
Industry: Medical - Biomedical and Genetics
Company: Exicure, Inc.
Industry: Medical - Biomedical and Genetics
2019 Financials; Lengthy Cash Runway; Near-Term Catalysts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Exicure, Inc.
Industry: Medical - Biomedical and Genetics
Equity Financing Completed; Multiple Programs Advancing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Exicure, Inc.
Industry: Medical - Biomedical and Genetics
First Neurology Development Program Revealed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Exicure, Inc.
Industry: Medical - Biomedical and Genetics
AST-008 Shows Additional Clinical Activity; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Exicure, Inc.
Industry: Medical - Biomedical and Genetics
Collaboration With Allergan on Hair Loss Therapeutics; 3Q19 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Exicure, Inc.
Industry: Medical - Biomedical and Genetics
Dynamic Drug Delivery for Oligos; Initiating at Buy and $8.00 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
|